Memantine for Cognitive Impairment in SLE

(ClearMEMory Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Leslie J Crofford, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Vanderbilt University Medical Center

Must not be taking: Opioids, Antidepressants, Stimulants, others

Disqualifiers: Severe psychiatric disease, Pregnancy, others

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but you cannot have changed medications that affect mood or cognition in the last 4 weeks. It's best to discuss your specific medications with the trial team.

What evidence supports the effectiveness of the drug Memantine for cognitive impairment in patients with systemic lupus erythematosus (SLE)?

Research suggests that Memantine, which blocks certain brain receptors, may help prevent brain damage and cognitive issues in SLE by stopping harmful antibodies from affecting the brain. This is based on studies showing Memantine's ability to protect brain cells in similar conditions. ^{1 2 3 4 5}

Is memantine safe for humans?

Memantine has been used safely in humans for conditions like dementia, and studies suggest it may prevent brain damage in lupus (SLE) by blocking harmful effects on brain cells. ^{1 2 3 6 7}

What makes the drug memantine unique for treating cognitive impairment in SLE?

Memantine is unique because it is an NMDA receptor antagonist that helps protect brain cells by reducing overstimulation from glutamate, which can cause damage. This mechanism is different from other treatments for cognitive impairment, as it specifically targets excitotoxicity, a process not addressed by many other drugs. ^{8 9 10 11 12}

Research Team

Leslie J Crofford, MD

Principal Investigator

Professor of Medicine - Rheumatology

Eligibility Criteria

This trial is for adults aged 18-60 with Systemic Lupus Erythematosus (SLE) who meet specific criteria and have cognitive symptoms. They must not use heavy drugs or alcohol, have had recent medication changes that affect mood/cognition, severe liver/renal disease, be pregnant, or involved in other drug studies.

Inclusion Criteria

I have reported symptoms of psychiatric issues related to lupus.

Score ≤ 85 on the RBANS total index (≤ 1 SD below the normative mean of 100)

Meet American College of Rheumatology (ACR) criteria for SLE

Exclusion Criteria

My liver tests are more than three times the normal limit or my kidneys work poorly.

I am younger than 18 or older than 60.

Inability or refusal to give informed consent for any reason including a diagnosis of dementia or significant cognitive impairment

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either memantine or placebo with dose escalation over 6 weeks, followed by a stable dose for an additional 6 weeks

12 weeks

Multiple visits for dose adjustments and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Memantine (NMDA Receptor Antagonist)
• Placebo (Other)

Trial Overview The study tests the safety and effectiveness of Memantine—an NMDA receptor antagonist—against a placebo over 14 weeks to reduce cognitive impairment in SLE patients. It includes blood and urine tests to monitor organ function and pregnancy status.

Participant Groups

Group I: Memantine Experimental Treatment 1 Intervention

At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.

Group II: Placebo Placebo Group 1 Intervention

At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials

922

Recruited

939,000+

Jeffrey R. Balser

Vanderbilt University Medical Center

Chief Executive Officer since 2009

MD and PhD from Vanderbilt University

Rick W. Wright

Vanderbilt University Medical Center

Chief Medical Officer since 2023

MD from University of Missouri-Columbia

Evergreen Therapeutics, Inc.

Industry Sponsor

Trials

5

Recruited

650+

The University of Texas Health Science Center, Houston

Collaborator

Trials

974

Recruited

361,000+

Dr. LaTanya Love

The University of Texas Health Science Center, Houston

Interim President

MD from UT Medical Branch in Galveston

Dr. Jagat Narula

The University of Texas Health Science Center, Houston

Chief Academic Officer since 2023

MD, PhD

The Cleveland Clinic

Collaborator

Trials

1,072

Recruited

1,377,000+

David Peter

The Cleveland Clinic

Chief Medical Officer

MD, board-certified in Hospice and Palliative Medicine

Tomislav Mihaljevic

The Cleveland Clinic

Chief Executive Officer since 2018

MD from University of Zagreb School of Medicine

Kleberg Foundation

Collaborator

Trials

1

Recruited

80+

Findings from Research

In a 12-week trial involving 51 patients with systemic lupus erythematosus (SLE), memantine did not show significant overall improvement in cognitive performance compared to a placebo, based on various neuropsychological assessments.

However, there was a notable improvement in the Controlled Oral Word Association Test for the memantine group at 12 weeks, suggesting a potential specific benefit in verbal fluency, although this was not observed in the broader cognitive assessments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Petri, M., Naqibuddin, M., Sampedro, M., et al.[2021]

In a study using MRL/lpr mice, memantine (MEM) showed some improvement in exploratory behavior, suggesting a potential role in addressing neuropsychiatric symptoms associated with systemic lupus erythematosus (SLE), but it did not prevent the overall development of CNS SLE-like symptoms.

Chronic treatment with MEM negatively impacted body growth and spontaneous activity in control mice, indicating that its effects are complex and may not solely target autoimmunity mechanisms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of prolonged treatment with memantine in the MRL model of CNS lupus. Marcinko, K., Parsons, T., Lerch, JP., et al.[2021]

In a study using mice that produce anti-DNA antibodies similar to those found in lupus patients, cognitive impairment and neuronal death occurred only after the blood-brain barrier was compromised, highlighting the role of the immune system in cognitive decline without direct CNS inflammation.

The NMDA receptor antagonist memantine was effective in preventing neuronal damage when administered before the triggering of the immune response, suggesting that NMDA receptor antagonists could be a potential new treatment strategy for cognitive dysfunction in lupus patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cognition and immunity; antibody impairs memory. Kowal, C., DeGiorgio, LA., Nakaoka, T., et al.[2022]

Memantine is an NMDA receptor antagonist that provides neuroprotective effects by reducing glutamate overstimulation, making it effective for treating moderate to severe Alzheimer's dementia without the adverse effects commonly seen with stronger antagonists.

It is the first drug approved for Alzheimer's treatment in both Europe and the United States, and ongoing research is exploring its potential benefits in earlier stages of Alzheimer's and other types of dementia, particularly when used in combination with cholinesterase inhibitors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[The clinical relevance of memantine use]. Sobów, T.[2013]

Memantine is an NMDA receptor antagonist that has shown neuroprotective and cognition-enhancing effects in animal models, and it has been clinically effective in improving cognitive performance in patients with Alzheimer's disease and vascular dementia.

Clinical trials have demonstrated that memantine is well-tolerated, with a low incidence of adverse events, making it a safe option for treating moderately severe to severe Alzheimer's disease, leading to its approval in both Europe and the US.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Memantine hydrochloride: pharmacological and clinical profile. Möbius, HJ., Stöffler, A., Graham, SM.[2017]

Memantine is an uncompetitive NMDA receptor antagonist that helps reduce glutamatergic excitotoxicity, showing modest improvement in clinical symptoms and potentially slowing disease progression in moderate-to-severe Alzheimer's disease and other forms of dementia.

Unlike cholinesterase inhibitors, which only provide symptomatic relief, memantine has been effective in severe stages of dementia and is the first drug to completely eliminate pendular nystagmus in multiple sclerosis patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Memantine: pharmacological properties and clinical uses. Kumar, S.[2013]

Memantine hydrochloride, an NMDA antagonist, was approved for the treatment of moderately severe-to-severe Alzheimer's disease in the EU, with marketing authorization expected in 2002, indicating its efficacy in managing this condition.

The drug is also being explored for various other conditions, including neuropathic pain and ocular diseases, showcasing its potential versatility beyond dementia treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Memantine. Merz. Kilpatrick, GJ., Tilbrook, GS.[2013]

References

1. United States pubmed.ncbi.nlm.nih.gov

Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. [2021]

2. United States pubmed.ncbi.nlm.nih.gov

Effects of prolonged treatment with memantine in the MRL model of CNS lupus. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Cognition and immunity; antibody impairs memory. [2022]

4. Canada pubmed.ncbi.nlm.nih.gov

Cognitive impairment in patients with systemic lupus erythematosus. [2006]

5. England pubmed.ncbi.nlm.nih.gov

An unusual case of inflammatory meningitis in a young man with systemic lupus erythematosus. [2018]

6. Netherlands pubmed.ncbi.nlm.nih.gov

Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. [2021]

7. Poland pubmed.ncbi.nlm.nih.gov

Cognitive impairment of MRL mice is related to NMDA receptor-mediated inflammatory response and production of adhesion molecules in MRL/lpr mice-derived micro-vascular endothelial cells. [2023]

8. United States pubmed.ncbi.nlm.nih.gov

Drug forecast: memantine, prototype of a new approach to treatment of dementia. [2006]

9. Poland pubmed.ncbi.nlm.nih.gov

[The clinical relevance of memantine use]. [2013]

10. Spain pubmed.ncbi.nlm.nih.gov

Memantine hydrochloride: pharmacological and clinical profile. [2017]

11. India pubmed.ncbi.nlm.nih.gov

Memantine: pharmacological properties and clinical uses. [2013]

12. England pubmed.ncbi.nlm.nih.gov

Memantine. Merz. [2013]